Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Laurie Miller Turner

Physician Assistant Florence, SC Physician Assistant

NPI 1467520213 CMS profile 11141123

214 W Pine St, Florence, SC 29501

Open in the dashboard

General payments

$5,333

332 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Laurie Miller Turner of Florence, SC is reported in the CMS Open Payments database as having received $5,333 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,013 66
2024 General $1,045 60
2023 General $1,164 65
2022 General $887 55
2021 General $1,224 86

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laurie Miller Turner
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Laurie Miller Turner were reported at $1,013. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Laurie Miller Turner Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,224 $132 $37–$438 $132
2022 $887 $155 $48–$522 $149
2023 $1,164 $167 $52–$557 $160
2024 $1,045 $178 $55–$600 $164
2025 $1,013 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $994 61 payments
  2. AstraZeneca Pharmaceuticals LP $540 30 payments
  3. Novo Nordisk Inc $482 32 payments
  4. Lilly USA, LLC $339 28 payments
  5. Amgen Inc. $330 19 payments
  6. GlaxoSmithKline, LLC. $328 17 payments
  7. Abbott Laboratories $314 20 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $243 15 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $216 12 payments
  10. Pfizer Inc. $168 11 payments
  11. Other $1,378 87 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,333 332 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $424 17 payments
  2. FARXIGA $345 18 payments
  3. UBRELVY $329 26 payments
  4. Repatha $303 17 payments
  5. Otezla $284 16 payments
  6. Ozempic $276 20 payments
  7. RYBELSUS $276 20 payments
  8. Kerendia $216 12 payments
  9. MOUNJARO $216 21 payments
  10. ZEPBOUND $205 19 payments
  11. Other $4,173 258 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 124 drugs

Part D claims

7,041

Median for Physician Assistant: 241

Drug cost

$593,223

Median for Physician Assistant: $4,110

Branded share of claims

20.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 152 $161,340
Jardiance Empagliflozin Brand 77 $72,620
Januvia Sitagliptin Phosphate Brand 52 $52,858
Ozempic Semaglutide Brand 44 $46,385
Farxiga Dapagliflozin Propanediol Brand 50 $40,049
Eliquis Apixaban Brand 30 $33,372
Repatha Sureclick Evolocumab Brand 21 $17,029
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 20 $13,312
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $12,258
Livalo Pitavastatin Calcium Brand 13 $10,568

The 10 drugs with the highest cost, of 124 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$80,326

Of which drugs: $12,797

Medicare patients

298

Average age 75

Services billed

21,167

181 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 32%
Ischemic heart disease 28%
Cancer 16%
Heart failure 13%
Chronic kidney disease 13%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 132 132 $10,499
Injection, methylprednisolone acetate, 1 mg J1010 Office 75 6,880 $649
Injection, methylprednisolone acetate, 80 mg J1040 Office 33 35 $92
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 28 91 $80

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $142
$142 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $88
$88 — —
UBRELVY
  • AbbVie, Inc. $69
$69 — —
Otezla
  • Amgen Inc. $50
$50 — —
Repatha
  • Amgen Inc. $50
$50 21 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record